Regenxbio Inc. entered an option and license agreement with Clearside Biomedical Inc. regarding its proprietary SCS Microinjector for the delivery of experimental treatment RGX-314 to a certain part of the eye.
Under the agreement, Regenxbio will pay an option fee to receive an exclusive, worldwide commercial license, with rights to sublicense, Clearside's SCS Microinjector for the delivery of AAV gene therapies for the treatment of multiple eye conditions, including wet age-related macular degeneration and diabetic retinopathy.
Additionally, Clearside will be eligible to receive up to $34 million in development milestones and up to $102 million in sales milestones and mid-single digit royalties on net sales of products using the microinjector.
Regenxbio will be responsible for the development and commercialization of gene therapy product candidates, while Clearside will be responsible for supplying the SCS Microinjector and supporting Regenxbio's preclinical and clinical studies along with commercial use.
Clearside's SCS Microinjector has been tested in over 1,000 injections during clinical trials, Regenxbio noted in its Sept. 4 press release.
Rockville, Md.-based Regenxbio plans to evaluate its one-time treatment RGX-314 using Clearside's SCS Microinjector for in-office, non-surgical delivery. The biotechnology company said it will continue to advance its RGX-314 delivery program.
